BEGIN:VCALENDAR
PRODID:-//Pixl8//MBS Eventfolio//EN
VERSION:2.0
X-WR-TIMEZONE:Europe/London
CALSCALE:GREGORIAN
METHOD:PUBLISH
CLASS:PUBLIC
BEGIN:VEVENT
DTSTART:20210916T105500
DTEND:20210916T110500
DTSTAMP:20260606T001452Z
UID:{ & stEvent.obj_id & }
LOCATION:
SUMMARY:Targeting the evolutionary RGD motif in the spike protein of SARS-CoV-2 serves as a novel treatment option to prevent vascular damage during COVID-19
DESCRIPTION:SARS-CoV-2, the virus that causes COVID-19, has developed a unique mutation that may play a role in disease transmission. Blocking its main receptor, ACE2, does not completely eliminate infection, suggesting the possibility of another receptor. Integrins are upregulated during COVID-19 and may be targeted by this evolutionary mutation. We have studied the mechanisms behind SARS-CoV-2 and integrin binding, and found this interaction may cause cardiovascular damage in severe COVID-19. In addition, we have investigated the integrin-blocker drug, Cilengitide, and its ability to prevent the virus from attaching to human cells, revealing the potential of a new antiviral treatment.
PRIORITY:1
END:VEVENT
END:VCALENDAR